GLP-1 agonists have been the most consequential development in metabolic medicine in at least a decade. Originally developed for type 2 diabetes, these drugs now have meaningful indications for weight management and cardiovascular risk reduction as well. The clinical impact is real. The marketing has outpaced the evidence in places, the side-effect profile is worth understanding before starting, and supervision matters more than the brand on the box. Here's a clinical view of where they fit in 2026.
TL;DR
- GLP-1 agonists work for type 2 diabetes, obesity, and (for some agents) cardiovascular risk reduction. The evidence is real.
- The 2026 landscape: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) dominate, with retatrutide (triple-action, Phase 3) and CagriSema (combo) likely arriving soon
- Choosing the right drug depends on goal, history, side-effect tolerance, and increasingly insurance coverage; brand recognition is the wrong basis for the choice
- The drug alone isn't enough: adequate protein (1.2-1.6 g/kg ideal body weight), resistance training, sleep, and a maintenance plan all matter
- Online-clinic prescribing without monitoring is creating preventable complications I'm seeing in my office
- To reach the practice: call 561-468-6981
How they work
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after meals. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. In type 2 diabetes, GLP-1 signaling is diminished, which contributes to the blood sugar problem.
The GLP-1 agonists are synthetic versions that do what the natural hormone does, more potently and for longer. That combination (better insulin response plus delayed stomach emptying plus reduced appetite) is why they work for both diabetes and weight.
The drugs in 2026
| Drug | Brand names | Dosing | Notes |
|---|---|---|---|
| Exenatide | Byetta, Bydureon | Twice daily / weekly | Older, less commonly started today |
| Liraglutide | Victoza, Saxenda | Daily injection | ~5 to 8% average weight loss |
| Dulaglutide | Trulicity | Weekly injection | Diabetes-focused |
| Semaglutide | Ozempic, Wegovy, Rybelsus | Weekly inj / daily oral | ~12 to 15% weight loss; best-studied class member |
| Tirzepatide | Mounjaro, Zepbound | Weekly injection | Dual GIP/GLP-1; ~15 to 20%+ weight loss |
| Retatrutide | Pipeline (Phase 3) | Weekly injection | Triple-action (GLP-1/GIP/glucagon); some trial patients lost over 24% |
| CagriSema | Pipeline | Weekly injection | Semaglutide + cagrilintide (amylin analog); strong trial efficacy |
Tirzepatide is technically a dual GIP/GLP-1 agonist, not a pure GLP-1. In practice it tends to produce the most weight loss of the currently-approved class. Retatrutide and CagriSema, both in late development, may push results further.
What they're actually used for
Type 2 diabetes
Meaningful A1C reduction, comparable to or better than most non-insulin options, with the added benefits of weight loss rather than weight gain and low risk of hypoglycemia. For patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, some GLP-1 agonists have clear data for reducing major cardiovascular events, which puts them high on the treatment algorithm. (How diabetes management works in concierge primary care.)
Obesity and weight management
Liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) are FDA-approved for weight loss. Average weight loss in trials: liraglutide ~5 to 8%, semaglutide ~12 to 15%, tirzepatide ~15 to 20% or more. Individual response varies.
The downstream benefits of meaningful weight loss are real: reduced risk of new-onset diabetes, lower blood pressure, improvement in sleep apnea severity, joint pain relief, lower risk of certain cancers, less progression of fatty liver disease. Mood, sleep, and exercise tolerance often improve too.
Cardiovascular protection
Independent of weight and glucose effects, some drugs in this class (semaglutide and liraglutide in particular) have data showing reduced risk of heart attack, stroke, and cardiovascular death in high-risk populations. This isn't a marketing claim; it's outcomes data from large randomized trials.
Side effects and contraindications
Most common: nausea, vomiting, diarrhea, constipation, abdominal discomfort. These are usually worst in the first few weeks after starting or after each dose increase and tend to ease over time. Slow titration helps significantly.
Less common but worth knowing: gallbladder issues, pancreatitis (rare), delayed gastric emptying that matters for anesthesia (let your anesthesiologist know before any procedure), injection-site reactions.
Contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2). Caution in active pancreatitis or severe gastroparesis.
Pregnancy: not appropriate during pregnancy or while attempting pregnancy. Stop well before trying to conceive.
How I approach the choice in my practice
In a 7-minute traditional visit, this conversation usually defaults to whatever the patient already heard about. In my practice it takes real time, and the steps are:
1. Clarify the goal. Are you primarily treating type 2 diabetes with weight loss as a secondary benefit? Treating obesity without diabetes? Maintaining weight loss you've already achieved? The answers shape both medication choice and dosing strategy.
2. Review the medical history carefully. Personal or family history of medullary thyroid cancer or MEN2 syndrome is an absolute contraindication. History of pancreatitis warrants careful consideration. Active gastroparesis is a significant concern. Pregnancy or active attempts to conceive require stopping. These screens matter and aren't negotiable.
3. Talk realistically about side effects. Nausea, constipation, sometimes vomiting. Worst during dose titration, typically easing over weeks. Patients need to know what to expect and how to manage it. Starting low and titrating slowly makes a significant difference in tolerability. Patients who stop after two weeks of nausea rarely had a chance to see the drug work.
4. Discuss the long view. These drugs work because they address the biology of appetite and satiety. That biology doesn't go away when you stop the drug. Most patients who stop regain weight. The realistic framing is usually a long-term commitment, not a short course.
The supervision issue
Online clinics prescribing these medications after a brief questionnaire have become common. I've seen patients come in after obtaining medications this way with complications that appropriate monitoring would have prevented.
GLP-1 management should include:
- Regular check-ins during titration and ongoing treatment
- Periodic lab work to monitor kidney function, liver function, and nutritional markers
- Monitoring for gallbladder issues, pancreatitis symptoms, or significant muscle loss
- Assessment of nutritional status; rapid weight loss without adequate protein and nutrient intake causes sarcopenia
- Review of other medications, particularly any that affect gastric motility or that might interact
- Counseling for patients undergoing surgery or anesthesia, since these drugs affect gastric emptying
None of this is exotic. It's the kind of monitoring appropriate for any potent medication, and it's the kind of monitoring a 7-minute visit usually doesn't accommodate. (What an annual physical looks like with the time to actually cover this.)
Why the medication alone isn't enough
The patients I see who do well on GLP-1s don't just take the drug. The results include not just weight loss but improvements in blood pressure, sleep apnea severity, joint pain, exercise tolerance, and cardiovascular risk markers. Patients treated as though the drug were a standalone solution tend to regain weight after stopping.
What actually matters alongside the medication:
- Adequate protein intake to preserve muscle mass during weight loss (usually 1.2 to 1.6 grams per kg of ideal body weight)
- Resistance training to maintain and build muscle
- Aerobic exercise for cardiovascular and metabolic benefit
- Sleep optimization, which affects appetite regulation directly
- Realistic expectations about the speed and trajectory of weight loss
- A plan for the maintenance phase, including whether and how the medication transitions
Duration and the maintenance question
For diabetes, typically long-term as part of overall management. For weight, the realistic framing is that these drugs work by addressing the biology of appetite and satiety; that biology doesn't go away when you stop the drug. Most patients who stop regain weight. Treatment is usually continued to maintain the result, though for some patients titrating down or using lower maintenance doses is a reasonable strategy worth working through with a physician who's actually seeing you regularly.
Frequently Asked Questions
Is Ozempic the same as Wegovy?
Same molecule (semaglutide), different brand and indication. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved for chronic weight management. Different dosing and different insurance pathways. Functionally similar in how they work in the body.
How much weight will I actually lose?
Trial data is the best benchmark we have. Liraglutide averages around 5 to 8% of body weight over a year; semaglutide averages around 12 to 15%; tirzepatide averages 15 to 20% or more. Individual response varies meaningfully, and trial averages assume a structured program that includes nutrition and lifestyle work alongside the drug. Patients who do less of that side rarely match the trial averages.
Can I get a GLP-1 if I don't have diabetes?
Yes, if you meet criteria for chronic weight management (typically BMI of 30+ or BMI of 27+ with a weight-related comorbidity). The FDA-approved options for non-diabetic weight management are liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). Insurance coverage for the obesity indication is more variable than for diabetes; many commercial plans don't cover it at all, which is why cash-pay or compounded versions have proliferated.
What about compounded semaglutide?
Compounded semaglutide became widely available during the FDA shortage period for the brand drugs. As shortages have resolved, the FDA has narrowed the legal pathway for compounding. Quality and consistency of compounded products vary significantly between sources. If cost is the issue driving the choice, it's worth a conversation with your physician about whether compounded sourcing is a reasonable bridge or whether the brand drug is now more accessible than it was. The safety considerations of supervision still apply either way.
What happens if I stop the medication?
Most patients regain weight after stopping, often substantially. The drugs work by altering appetite and satiety signaling, and that signaling reverts when the drug is gone. Some patients can step down to lower maintenance doses; some need to stay on full dosing indefinitely; a smaller subset can stop and hold weight if they've built strong lifestyle infrastructure. The realistic framing is to plan for long-term treatment from the start.
Are there any patients who shouldn't take these drugs?
Yes. Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active or recent pancreatitis, severe gastroparesis, pregnancy or planned pregnancy. Caution in patients with significant gallbladder disease history, severe kidney disease, or those on multiple medications that affect gastric motility. The screening conversation is part of starting the drug responsibly.
How I think about these drugs in my practice
GLP-1 agonists are one of the more significant clinical developments I've seen in internal medicine. Used thoughtfully, in the right patients, with appropriate dosing and monitoring, they change outcomes that previously were hard to change. The popular hype glosses over the side effects, the cost, the duration of treatment, and the patient selection. In a real clinical setting, all of those matter, and a concierge practice has the time to handle them properly.
How to evaluate any practice for GLP-1 supervision
The criterion is whether you'll actually be seen by the same physician regularly enough that the monitoring above is real, not theoretical. Panel size below 300 is a reasonable proxy. (Full criteria for evaluating any concierge practice.)
About the Author
Dr. Ben Soffer, DO is a board-certified physician practicing concierge primary care in Boca Raton, Florida. He caps his practice at 50 patients, which makes the kind of close GLP-1 monitoring described above the actual operating model rather than a theoretical possibility.
If you want to talk through whether a GLP-1 makes sense for you
A no-obligation conversation about your specific situation, whether you're considering starting one or already on one and want closer oversight than you're getting.
- Call: 561-468-6981
- Email: info@drbensoffer.com
- Or reach out through the contact form
